Source:http://linkedlifedata.com/resource/pubmed/id/17950805
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2007-10-22
|
pubmed:abstractText |
Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration's criteria for appetite suppressant-induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of > or =2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 +/- 9.8% and 5 +/- 1.3%, respectively (p = 0.007). Tricuspid regurgitation > or =2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The mean tricuspid regurgitant area ratios were 19 +/- 9.5% and 9 +/- 4.5%, respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 0.11). Valvular "strands" were present in 6 MDMA users (21%) and in none of the controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular heart disease and valvular strands.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0002-9149
|
pubmed:author |
pubmed-author:BechetSergeS,
pubmed-author:BenjaminScottS,
pubmed-author:CloseLaurentL,
pubmed-author:CosynsBernardB,
pubmed-author:CreetenEdwinE,
pubmed-author:D'haenenHugoH,
pubmed-author:DroogmansStevenS,
pubmed-author:FrankenPhilippe RPR,
pubmed-author:KemdemArsèneA,
pubmed-author:SchoorsDannyD,
pubmed-author:Van CampGuyG,
pubmed-author:VandenbosscheJean-LucJL,
pubmed-author:WeytjensCarolineC
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
100
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1442-5
|
pubmed:meshHeading |
pubmed-meshheading:17950805-Adult,
pubmed-meshheading:17950805-Dose-Response Relationship, Drug,
pubmed-meshheading:17950805-Female,
pubmed-meshheading:17950805-Hallucinogens,
pubmed-meshheading:17950805-Heart Valve Diseases,
pubmed-meshheading:17950805-Humans,
pubmed-meshheading:17950805-Logistic Models,
pubmed-meshheading:17950805-Male,
pubmed-meshheading:17950805-N-Methyl-3,4-methylenedioxyamphetamine,
pubmed-meshheading:17950805-Substance-Related Disorders
|
pubmed:year |
2007
|
pubmed:articleTitle |
Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.
|
pubmed:affiliation |
Department of Cardiology, Universitair Ziekenhuis Brussel, Brussels, Belgium. steven_droogmans@yahoo.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|